(IRMD) Iradimed - Ratings and Ratios
Exchange: NASDAQ • Country: United States • Currency: USD • Type: Common Stock • ISIN: US46266A1097
IRMD: MRI, Infusion Pumps, Monitoring Systems, IV Poles, Sensors
Iradimed Corporation is a developer and manufacturer of MRI-compatible medical devices, focusing on creating innovative solutions for hospitals, acute care facilities, and outpatient imaging centers. Their product portfolio includes the MRidium MRI-compatible intravenous infusion pump system, which is designed to provide safe and accurate infusion therapy during MRI procedures. This system is complemented by disposable IV tubing sets, ensuring a seamless and hygienic experience for patients. Additionally, the company offers an MRI-compatible patient vital signs monitoring system, enabling healthcare professionals to track critical patient data in real-time, even in the presence of strong magnetic fields.
The company's product line also features the 3600 FMD1 with RALU ferromagnetic detection device, which plays a crucial role in ensuring the safety of patients and medical staff during MRI procedures. This device is capable of detecting ferromagnetic objects, helping to prevent accidents and injuries. Furthermore, Iradimed provides a range of accessories, including non-magnetic IV poles, wireless remote displays and controls, side car pump modules, and dose error reduction systems. These accessories are designed to enhance the functionality and usability of the company's core products, while also improving patient outcomes and reducing the risk of medical errors.
In terms of distribution, Iradimed employs a multi-channel approach, utilizing direct field sales representatives, regional sales directors, clinical application specialists, and independent distributors to reach its target markets. This strategy enables the company to effectively serve its customers in the United States and internationally, providing them with access to its innovative MRI-compatible medical devices and related accessories. With a strong online presence, including its website at https://www.iradimed.com, Iradimed is well-positioned to continue growing its customer base and expanding its market share in the healthcare equipment industry.
As a publicly traded company, Iradimed Corporation is listed on the NASDAQ stock exchange under the ticker symbol IRMD, with its common stock classified under the GICS sub-industry of Health Care Equipment. Incorporated in 1992 and headquartered in Winter Springs, Florida, the company has established itself as a leading provider of MRI-compatible medical devices and accessories, with a strong focus on innovation, quality, and customer satisfaction. With its ISIN code US46266A1097, Iradimed is committed to delivering value to its shareholders, customers, and patients, while contributing to the advancement of the healthcare industry as a whole.
Additional Sources for IRMD Stock
Tweets: X Stocktwits
Fund Manager Positions: Dataroma Stockcircle
IRMD Stock Overview
Market Cap in USD | 700m |
Sector | Healthcare |
Industry | Medical Devices |
GiC Sub-Industry | Health Care Equipment |
IPO / Inception | 2014-07-16 |
IRMD Stock Ratings
Growth 5y | 79.0% |
Fundamental | 71.3% |
Dividend | 4.24% |
Rel. Strength Industry | 28.2 |
Analysts | 4.5/5 |
Fair Price Momentum | 55.92 USD |
Fair Price DCF | 8.50 USD |
IRMD Dividends
Dividend Yield 12m | 0.86% |
Yield on Cost 5y | 1.82% |
Annual Growth 5y | -23.37% |
Payout Consistency | 81.4% |
IRMD Growth Ratios
Growth Correlation 3m | 82.8% |
Growth Correlation 12m | 93.5% |
Growth Correlation 5y | 86.9% |
CAGR 5y | 17.86% |
CAGR/Max DD 5y | 0.36 |
Sharpe Ratio 12m | 1.03 |
Alpha | 15.07 |
Beta | 1.06 |
Volatility | 30.56% |
Current Volume | 51.9k |
Average Volume 20d | 44.8k |
As of February 23, 2025, the stock is trading at USD 56.24 with a total of 51,919 shares traded.
Over the past week, the price has changed by +1.83%, over one month by -6.78%, over three months by +5.65% and over the past year by +31.12%.
Yes, based on ValueRay Fundamental Analyses, Iradimed (NASDAQ:IRMD) is currently (February 2025) a good stock to buy. It has a ValueRay Fundamental Rating of 71.32 and therefor a positive outlook according to the companies health.
Based on ValueRays Analyses, Dividends and Discounted-Cash-Flow, the Fair Value of IRMD as of February 2025 is 55.92. This means that IRMD is currently overvalued and has a potential downside of -0.57%.
Iradimed has received a consensus analysts rating of 4.50. Therefor, it is recommend to buy IRMD.
- Strong Buy: 1
- Buy: 1
- Hold: 0
- Sell: 0
- Strong Sell: 0
According to ValueRays Forecast Model, IRMD Iradimed will be worth about 67.1 in February 2026. The stock is currently trading at 56.24. This means that the stock has a potential upside of +19.33%.
Issuer | Forecast | Upside |
---|---|---|
Wallstreet Target Price | 71 | 26.2% |
Analysts Target Price | 65 | 15.6% |
ValueRay Target Price | 67.1 | 19.3% |